Pediatric Lipid Disorders Flashcards
7 cards from real CLS practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 Pediatric Lipid Disorders flashcards as text
Which physical finding is pathognomonic for homozygous familial hypercholesterolemia in children?
Answer: Planar xanthomas in the interdigital web spaces
Planar or tuberous xanthomas over the hands, elbows, knees, and interdigital spaces are hallmark findings in homozygous FH.
Which medication class is used as an adjunct to statins in children with familial hypercholesterolemia who need additional LDL-C lowering?
Answer: Bile acid sequestrants
Bile acid sequestrants (e.g., colesevelam) are approved for pediatric use and provide additive LDL-C lowering with statins.
A 14-year-old male with heterozygous FH initiates statin therapy. What baseline laboratory test is most important to obtain?
Answer: Creatine kinase and hepatic transaminases
Baseline CK and liver function tests (AST/ALT) should be obtained prior to statin initiation to monitor for myopathy and hepatotoxicity.
Which apolipoproteins are elevated in children with familial combined hyperlipidemia?
Answer: ApoB and ApoC-III
Familial combined hyperlipidemia is characterized by overproduction of ApoB-containing particles, with elevated ApoB and often ApoC-III.
Which genetic disorder causing elevated LDL-C in children is transmitted in an autosomal recessive pattern?
Answer: Sitosterolemia
Sitosterolemia (phytosterolemia) is an autosomal recessive disorder caused by ABCG5/ABCG8 mutations leading to plant sterol accumulation.
A child with sitosterolemia should be treated primarily with which medication?
Answer: Ezetimibe
Ezetimibe inhibits NPC1L1-mediated sterol absorption in the gut, making it the drug of choice for sitosterolemia.
What is the significance of measuring Lp(a) in children with familial hypercholesterolemia?
Answer: It identifies those at higher cardiovascular risk requiring more aggressive therapy
Elevated Lp(a) in children with FH confers additional atherosclerotic cardiovascular risk beyond LDL-C and should guide therapy intensity.
How this page was made: written with AI tools. Exam facts are checked against the official sources listed below. Not reviewed by a subject-matter expert. Editorial policy
Sources & references
Exam facts on this page (fees, format, dates, passing scores) are checked against these official sources; the date is our last check. Editorial policy
- lipidboard.org — Renewal, score validity, test delivery, exam format, time limit, fees, registration deadline, test dates · verified Oct 2026